Key result
Nifekalant significantly increased 24-hour survival compared to lidocaine (53% vs 31%, OR 3.16) in patients with out-of-hospital cardiac arrest due to shock-refractory ventricular fibrillation.
Why the study?
Does nifekalant improve short-term survival compared to lidocaine in patients with out-of-hospital cardiac arrest due to shock-refractory ventricular fibrillation?
Cohort (n=120)
No
Does nifekalant improve short-term survival compared to lidocaine in patients with out-of-hospital cardiac arrest due to shock-refractory ventricular fibrillation?
Odds Ratio: 3.16 (95% CI 1.4–7.17)
Absolute Event Rate: 53% vs 31%
p-value: p=<0.01
In patients with out-of-hospital cardiac arrest and shock-refractory ventricular fibrillation, nifekalant significantly improved survival to hospital admission and 24-hour survival compared to a historical cohort receiving lidocaine.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice in refractory VF arrest; leaves open whether nifekalant improves outcomes versus current standards in randomized trials.
Tahara et al. (2006) conducted a cohort in Out-of-hospital cardiac arrest with shock-refractory ventricular fibrillation (n=120). Nifekalant vs. Lidocaine (1.5 mg/kg intravenous) was evaluated on 24-hour survival (OR 3.16, 95% CI 1.40-7.17, p=<0.01). Nifekalant significantly increased 24-hour survival compared to lidocaine (53% vs 31%, OR 3.16) in patients with out-of-hospital cardiac arrest due to shock-refractory ventricular fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: